Reliance Global Group Completes Sale of Altruis Benefit Consulting for $8 Million in Cash Plus Up to $1 Million Earnout

Reliance Global Group completed the sale of its Altruis Benefit Consulting subsidiary for an $8.0 million cash purchase price, plus a potential $1.0 million earnout over three years; the buyer's $3.1 million secured promissory note was repaid in full on September 30. The company has received approximately $7.5 million in cash, with $461,729 retained as indemnity and working-capital holdbacks. The second non-core agency sale completed in September is intended to strengthen liquidity and fund investment in Reliance's AI platform and RELI Exchange InsurTech network.

Analysis

EZRA is exchanging recurring agency EBITDA for a one-time liquidity event; the valuation implication depends entirely on whether the realized proceeds exceed the disposed unit's contribution at a credible multiple. The near-term benefit is reduction in financing and listing-risk pressure if cash remains unrestricted, but only a fraction of headline consideration is immediately deployable after holdbacks, transaction costs, and potential working-capital adjustments. The earnout should be assigned little value until the buyer demonstrates qualifying revenue growth.

The market may initially reward a cleaner balance sheet and reduced dilution risk over the next days to weeks, particularly for a micro-cap where liquidity events can matter more than operating earnings. Over the next 1-3 months, the critical catalyst is a filing that reconciles cash received, debt repayment, and pro-forma revenue/EBITDA lost from both agency sales. A lower-revenue, higher-multiple AI narrative will not sustain without measurable RELI Exchange adoption, unit economics, or external customer revenue; otherwise the company risks multiple compression as investors view the strategy as shrinking the legacy earnings base.

Contrarian view: the sale is not automatically value-creative simply because it raises cash. If remaining agency operations carry the fixed public-company cost base while AI investment rises, cash burn can accelerate despite headline balance-sheet improvement. The structural upside over 6-18 months requires management to convert sale proceeds into recurring software-like gross profit before the monetized agency cash flows would have been replaced; absent that evidence, EZRA remains a financing-risk watch rather than a durable InsurTech rerating.

Key Decisions for Investors

• No new directional position before the next 10-Q/8-K provides pro-forma revenue, EBITDA and cash-flow contribution of Altruis and the prior agency divestiture. Treat disclosure of net cash retained and debt reduction as the immediate gating catalyst.
• For existing EZRA exposure, retain only a small event-driven position through the next filing; add only if unrestricted cash rises by roughly the expected net proceeds while annualized cash burn does not increase. Exit if management funds AI initiatives without disclosed commercial KPIs or if cash falls materially versus the post-sale baseline.
• Use any sharp press-release-driven rally to reduce exposure unless accompanied by independently verifiable RELI Exchange metrics: paying customers, recurring revenue, retention, and gross margin. A balance-sheet transaction alone does not justify a software multiple.
• Set a 1-3 month alert for Nasdaq compliance disclosures, equity issuance, or new debt. Any such financing shortly after asset monetizations would falsify the deleveraging/liquidity thesis and materially increase dilution risk.